Abstract
Objectives This study evaluated the effects of dexmedetomidine, ketamine, and midazolam on oxidative stress, neuronal injury, and inflammation in a rat traumatic brain injury (TBI) model by measuring malondialdehyde (MDA), S100B, total antioxidant status (TAS), and tumor necrosis factor-alpha (TNF-α) in brain tissue homogenates and serum.Methods Forty adult male rats were randomized into five groups (n = 8): Sham (S), TBI (T), TBI + Dexmedetomidine (D), TBI + Ketamine (K), and TBI + Midazolam (M). TBI was induced using the controlled cortical impact method. Study drugs were administered intraperitoneally 30 minutes after trauma. At 24 hours, blood and brain samples were collected, and homogenates were prepared. MDA, S100B, TAS, and TNF-α were quantified using validated biochemical assays.Results Relative to Sham, the TBI group showed significantly higher MDA, S100B, and TNF-α and lower TAS in both tissue and serum (p < 0.05). Dexmedetomidine significantly increased TAS and reduced MDA, S100B, and TNF-α in both compartments (p < 0.01). Ketamine produced a pronounced reduction in MDA (p < 0.01), with limited effects on S100B, TAS, and TNF-α. Midazolam yielded partial improvement, mainly lowering TNF-α, without significant changes in the other markers.Conclusion Among the tested agents, dexmedetomidine provided the most robust protection against oxidative stress, neuronal injury, and inflammation after TBI. Ketamine and midazolam conferred moderate benefits. These data suggest dexmedetomidine may be a more effective option for mitigating secondary brain injury following traumatic insult and support further translational studies to clarify optimal dosing, timing, and mechanisms. Findings align with neuroprotective profiles previously reported for dexmedetomidine in TBI.